Search
Clinician Ordering Portal
Scientific evidence
Incorporating the 31-gene expression profile test stratifies survival outcomes and leads to improved survival compared to clinicopathologic factors alone: a surveillance, epidemiology and end results (SEER) program collaboration
Apr 2022
Utilizing patient data provided through collaboration with the NCI SEER program in patients with Stage I-III CM, 31-GEP class result was a significant independent predistor of both MSS and OS. Patients with 31-GEP results in addition to clinicopathologic factors had improved survival.
Publication: Poster, presented at the 18th European Association of Dermato Oncology (EADO) Congress, Seville Spain, April 21-23 2022.
Development and validation of a nomogram incorporating gene expression profiling and clinical factors for accurate prediction of metastasis in patients with cutaneous melanoma following MOHS micrographic surgery
Apr 2022
Prospective multicenter study showed that integration of 31-GEP and T stage can gain clinically useful prognostic information from data obtained noninvasively.
Publication: Journal of the American Academy of Dermatology
Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th edition staging
Apr 2022
DecisionDx-Melanoma data significantly stratified MSS in stage I, II, and III patients. This test has also demonstrated high specificity and NPV for melanoma-specific mortality (MSM).
Publication: Melanoma Research
Expert consensus on the use of prognostic gene expression profiling tests for the management of cutaneous melanoma: consensus from the skin cancer prevention working group
Mar 2022
Expert panel of 8 dermatologists from the Skin Cancer Prevention Working Group developed 6 concensus statements supporting the appropriate use of GEP testing.
Publication: Dermatology and Therapy
Analytical validity of DecisionDx-SCC, a gene expression profile test to identify risk of metastasis in cutaneous squamous cell carcinoma (SCC) patients
Feb 2022
To improve identification of patients with cutaneous squamous cell carcinoma (SCC) at high risk for metastatic disease, the DecisionDx-SCC assay, a prognostic 40-gene expression profile (40-GEP) test, was developed and validated.
Publication: Diagnostic Pathology
Using a 31-gene expression profile test to stratify patients with stage I–II cutaneous melanoma according to recurrence risk: update to a prospective, multicenter study
Feb 2022
The 31-GEP accurately identified patients with stage IB-II CM at low and high risk of melanoma relapse in a prospective, multicenter study. Identifying which tumors have the highest probability of recurrence or metastasis, despite negative SLN results can aid in earlier disease detection.
Publication: Cancers
Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study
Feb 2022
Final report from a prospective study assessing the impacy of 31-GEP testing results on clinical management decisions including changes in imaging, laboratory work, and frequency of office visits. Outcomes data included.
Publication: Current Medical Research and Opinion
Clinical utility of the 40-gene expression profile (40-GEP) test for improved patient management decisions and disease-related outcomes when combined with current clinicopathological risk factors for cutaneous squamous cell carcinoma (cSCC): case series
Feb 2022
While improvements have been made to risk assessment of cutaneous squamous cell carcinoma (cSCC) patients, there is a critical need for a uniform and more precise stratification system of their care.
Publication: Dermatol Ther
Current methods and caveats to risk factor assessment in cutaneous squamous cell carcinoma (cSCC): a narrative review.
Feb 2022
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer, and the number of deaths due to cSCC is estimated to be greater than the number attributed to melanoma.
Publication: Dermatol Ther
Gene expression profiling for metastatic risk in head and neck cutaneous squamous cell carcinoma
Jan 2022
Over 50% of newly diagnosed cutaneous squamous cell carcinoma (cSCC) lesions occur in the head and neck (cSCC‐HN), and metastasis to nodal basins in this region further complicates surgical and adjuvant treatment.
Publication: Laryngoscope Investig Otolaryngol.
Molecular research in uveal melanoma: ushering in a new standard of care
Jan 2022
Publication: Retina Times
Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test
Nov 2021
To clinically validate the 40-gene expression profile (40-GEP) test for cutaneous squamous cell carcinoma patients and evaluate coupling the test with individual clinicopathologic risk factor-based assessment methods.
Publication: Future Oncology